These statistics indicate approximately 6 to 7 out of every 100 patients taking semaglutide for weight loss over three years will suffer permanent vision loss a risk many allege they were never warned about
In a study comparing the two drugs for weight loss, people lost an average of 5.9% of their body weight in three months with Tirzepatide, compared to 3.6% with Semaglutide [1]
We also need to know that 1 mL of liquid is the same as 100 units on a standard insulin syringe
Yet, in many countries the devices being used to deliver GLP-1s are the same for both the weight loss and T2D populations and, in many cases, were originally designed for delivering insulin, such as Novo Nordisks FlexTouch pen (Wegovy, semaglutide) or Eli Lillys KwikPen (Mounjaro, tirzepatide) outside the US
The Z factor value for the assay was 0.73 (Supplementary Fig
More on charging later